Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Sees Significant Decrease in Short Interest

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX - Get Free Report) was the target of a significant decrease in short interest during the month of March. As of March 31st, there was short interest totalling 226,000 shares, a decrease of 22.9% from the March 15th total of 293,200 shares. Based on an average daily volume of 1,520,000 shares, the days-to-cover ratio is presently 0.1 days. Currently, 2.9% of the shares of the stock are short sold.

Wall Street Analysts Forecast Growth

Separately, StockNews.com upgraded shares of Cumberland Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Thursday, March 6th.

Cumberland Pharmaceuticals Stock Performance

Shares of CPIX traded down $0.34 during midday trading on Thursday, reaching $4.84. The stock had a trading volume of 26,329 shares, compared to its average volume of 863,167. The firm has a 50 day simple moving average of $4.86 and a 200-day simple moving average of $3.04. Cumberland Pharmaceuticals has a one year low of $1.04 and a one year high of $7.25. The firm has a market cap of $67.61 million, a PE ratio of -6.29 and a beta of -0.24. The company has a current ratio of 1.13, a quick ratio of 0.99 and a debt-to-equity ratio of 0.41.

Cumberland Pharmaceuticals (NASDAQ:CPIX - Get Free Report) last issued its earnings results on Tuesday, March 4th. The specialty pharmaceutical company reported ($0.03) earnings per share for the quarter. Cumberland Pharmaceuticals had a negative net margin of 29.54% and a negative return on equity of 9.50%. The business had revenue of $10.44 million during the quarter.

Hedge Funds Weigh In On Cumberland Pharmaceuticals

An institutional investor recently raised its position in Cumberland Pharmaceuticals stock. Two Sigma Investments LP grew its stake in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX - Free Report) by 94.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 37,649 shares of the specialty pharmaceutical company's stock after purchasing an additional 18,271 shares during the quarter. Two Sigma Investments LP owned approximately 0.27% of Cumberland Pharmaceuticals worth $89,000 at the end of the most recent reporting period. Institutional investors own 15.51% of the company's stock.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.